IDSA and HIVMA On Funding Package

The bipartisan bill passed by the House and the Senate and signed by the president provides urgently needed resources to confront COVID-19, funds critical programs across the government in 2021 and offers great hope for recovery from some of the pandemic’s damaging impacts in the year to come.

Response from IDSA President Barbara Alexander MD, MHS, FIDSA, to FDA EUA of Moderna COVID-19 Vaccine: Let’s make the most of this moment

The emergency use authorization of a second COVID-19 vaccine today means that millions more people can be immunized against this virus in the weeks to come.

Response from IDSA President Barbara Alexander MD, MHS, FIDSA to FDA EUA of Pfizer-BioNTech COVID-19 Vaccine: FDA Authorization Is First of Critical Steps Ahead

“The first Emergency Use Authorization of a vaccine against the novel coronavirus in the United States offers a promising opportunity to reverse the trajectory of the COVID-19 pandemic." Read Full Statement

Commemorate Progress, Resilience This World AIDS Day

In the face of new challenges to the access to testing, prevention, care and treatment necessary to stop HIV transmissions, infections, illnesses and deaths at home and globally, the theme of this year’s World AIDS Day: Ending the HIV/AIDS Epidemic: Resilience and Impact must drive the efforts ahead.

HIVMA Recognizes Excellence in HIV Clinical Care, Education With 2020 Awards

Honoring careers in research, clinical care and education that have resulted in significant improvements or discoveries in HIV care, the HIV Medicine Association presented its 2020 Awards for Excellence to Adaora Adimora, M.D., FIDSA, and Gabriel Chamie, M.D., MPH, in October.

Barbara D. Alexander, M.D., MHS, FIDSA – President, Infectious Diseases Society of America on CDC’s Advisory Committee on Immunization Practices’ Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine:

The four principles established by CDC’s Advisory Committee on Immunization Practices’ Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine set a positive course for mitigating and containing the impacts of the pandemic.

IDSA Response to Pfizer Request for COVID-19 Vaccine EUA

Barbara D. Alexander, M.D., MHS, FIDSA – President, Infectious Diseases Society of America on today’s Pfizer/BioNTech application for Emergency Use Authorization of its COVID-19 vaccine candidate

This Holiday Season Can Stand as a Turning Point in Our Nation’s Control of the COVID-19 Pandemic

With numbers of infections, illnesses, hospitalizations and deaths caused by COVID-19 at record highs as this holiday season begins, the risks posed by the spread of the coronavirus are more dangerous than at any time since its emergence last December.

Statement on the Emergency Use Authorization of Bamlanivimab

We share and appreciate the urgency in expanding therapeutic options for COVID-19 as daily case counts and hospitalization rates reach record levels. For new therapeutics to be used widely and routinely outside of clinical trials, we urge that there be sufficient safety and efficacy data to be confident regarding their use.

Senate Releases Appropriations With Continued Funding for the Ending the HIV Epidemic Initiative

The Senate Appropriations Committee’s funding proposal for FY2021 makes critical investments in the Ending the HIV Epidemic initiative and NIH but fails to include COVID-19 relief funding.

IDSA and HIVMA Congratulate the President-elect, Offer Guidance on Pandemic Response

The Infectious Diseases Society of America and its HIV Medicine Association have reached out today to President-elect Joe Biden to congratulate him and to offer their memberships’ expertise as the new administration takes on the challenges of the COVID-19 pandemic and other infectious diseases threats.

IDSA and HIVMA Release New Comprehensive Primary Care Guidance for People with HIV

New guidance published today by an expert panel of the HIV Medicine Association of the Infectious Diseases Society of America updates the 2013 guideline for providing comprehensive evidence-based primary care to people with HIV.